Galafold, migalastat
Named-patient access overview. Galafold is coordinated by Reserve Meds for international patients via physician-led cross-border sourcing.
About Galafold
Galafold (migalastat) is manufactured by Amicus Therapeutics and indicated for Fabry disease in patients with amenable GLA variants. It is an oral small molecule (pharmacological chaperone) approved by the US FDA in 2018 and may be accessible to international patients through Named Patient Program or personal-import pathways.
How Reserve Meds coordinates Galafold
- Patient or treating physician submits a named-patient request.
- Clinical team verifies appropriateness of Galafold for the patient and destination country.
- Treating physician issues prescription and clinical justification.
- Country-specific NPP / personal-import documentation is prepared.
- Galafold is sourced from a DSCSA-compliant US specialty wholesaler with full serial traceability.
- Shipment is coordinated to the patient's physician or hospital pharmacy (cold-chain where required).
Country coverage
Reserve Meds publishes detailed country deep-dives for our most-requested medications. Galafold country deep-dives are not yet published; we are expanding coverage as the cohort grows. If you are pursuing Galafold for a patient in the UAE, Saudi Arabia, India, Egypt, Pakistan, or another market we serve, submit a request and our clinical team will match the destination to the appropriate regulatory pathway and timeline.
Reserved for you. Galafold is in coordination scope for the first cohort. Country-specific pricing and timing are confirmed once a coordinator reviews your case.
Start a request for Galafold
Submit a 60-second intake. Our clinical team will reach out as our first cohort opens with case-specific feasibility, timeline, and a formal quote.